Metabolism and disposition of novel des-fluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters

Drug Metabolism and Disposition

Volumn 31, Issue 11, 2003, Pages 1409-1418

  Hayakawa, Hiroyoshi ^a   Fukushima, Yoko ^a   Kato, Hiroshi ^a   Fukumoto, Hiroyuki ^a   Kadota, Takumi ^a   Yamamoto, Hiroyuki ^a   Kuroiwa, Hiroyuki ^b   Nishigaki, Junko ^b   Tsuji, Akira ^c  

^a TOYAMA CHEMICAL CO LTD   (Japan)

^b Institute of Whole Body Metabolism   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DESFLUOROQUINOLONE DERIVATIVE; DRUG METABOLITE; GARENOXACIN; GLUCURONIDE; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BILE FLOW; BLOOD; COMPARATIVE STUDY; DISTRIBUTION VOLUME; DOG; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; DRUG METABOLISM; EXPERIMENTAL ANIMAL; MACACA; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SPECIES DIFFERENCE; URINARY EXCRETION;

ANIMALS; DOGS; FLUOROQUINOLONES; MACACA FASCICULARIS; MALE; RATS; RATS, WISTAR; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS; MACACA;

EID: 0142181021     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.11.1409     Document Type: Article

References (35)

1. Bello A, Hollenbaugh D, Gajjar D, Christopher L, and Grasela D (2001) Ex vivo serum protein binding of BMS-284756: impact on the unbound AUC/MIC ratio for Streptococcus pneumoniae. in Program and Abstracts of the Forty-First Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago. IL. pp 8, A45, American Society for Microbiology, Washington, DC.
2. Boxenbaum H (1984) Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 15:1071-1121.
3. Brown SY, Garland WA, and Fukuda EK (1990) Isolation and characterization of an unusual glucuronide conjugate of rimantadine. Drug Metab Dispos 18:546-547.
4. Dalvie DK, Khosla NB, Navetta KA, and Brighty KE (1996) Metabolism and excretion of trovafloxacin, a new quinolone antibiotic, in Sprague-Dawley rats and beagle dogs. Effect of bile duct cannulation on excretion pathways. Drug Metab Dispos 24:1231-1240.
5. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
6. Domagala JM (1994) Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 33:685-706.
7. Dow J, Piriou F, Wolf E, Dulery BD, and Haegele KD (1994) Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans. Drug Metab Dispos 22:738-749.
8. Efthymiopoulos C, Battaglia R, and Strolin Benedetti M (1991) Animal pharmacokinetics and interspecies scaling of FCE22101, a penem antibiotic. J Antimicrob Chemother 27:517-526.
9. Feng MR, Loo J, and Wright J (1998) Disposition of the antipsychotic agent C1-1007 in rats, monkeys, dogs and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling. Drug Metab Dispos 26:982-988.
10. Forrest A, Chodosh S, Amantea MA, Collins DA, and Schentag JJ (1997) Pharmacokinetics and pharmacodynamics of oral grepafloxacin patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 40 (Suppl A): 45-57.
11. Fukumoto H, Matsutani H, Yamamoto Y, and Sakai H (2003) Determination of 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2, 3-dihydro-1H-5-isoindolyl]-4-oxo-1, 4-dihydro-3-quinolinecarboxylic acid (T-3811) and its sulfate conjugate metabolite (T-3811M1) in human plasma and urine using liquid chromatography-mass spectrometry. Iyakuhinn Kenkyu 34:153-163.
12. Fung-Tomc JC, Minassian B, Kolek B, Huczko E, Aleksunes L, Stickle T, Washo T, Gradelski E, Valera L, and Bonner DP (2000) Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob Agents Chemother 44:3351-3356.
13. Furuhata K, Fukuda H, Soumi K, Shimamoto A, Nakamura T, Todo Y, Terashima N, Watanabe Y, and Narita H (2000) The influence of BMS-284756 (T-3811ME) on metabolism of theophylline and activity of cytochrome P450 in human and rat microsomes, in Program and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Canada. pp 37, A2263, American Society for Microbiology, Washington, DC.
14. Gajjar D, Russo R, Bello A, Christopher L, Geraldes M, and Grasela D (2001) Safety, tolerability and pharmacokinetics of intravenous BMS-284756 in healthy subjects, in Program and Abstracts of the Forty-First Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL. pp 8, A44, American Society for Microbiology, Washington, DC,
15. Grindel JM, Jaworski T, Emanuele RM, and Culbreth P (2002) Pharmacokinetics of a novel surface-active agent, purified poloxamer 188, in rat, rabbit, dog and man. Biopharm Drug Dispos 23:87-103.
16. 14C] T-3761 in rats and mice. Jpn J Antibiot 48:671-685.
17. Hayakawa H, Takagi K, Fukushima Y, Kawamura Y, and Tsuji A (2002) Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats. J Pharm Pharmacol 54:1229-1236.
18. Hayashi K, Takahata M, Kawamura Y, and Todo Y (2002) Synthesis, antibacterial activity and toxicity of 7-(isoindolin-5-yl)-4-oxoquinoline-3-carboxylic acid. Discovery of the novel des-F(6)-quinolone antibacterial agent garenoxacin (T-3811 or BMS-284756). Arzneim-Forsch/ Drug Res 52:903-913.
19. Hyatt JM, McKinnon PS, Zimmer GS, and Schentag JJ (1995) The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 28:143-160.
20. Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, and Coassolo P (1997) Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 86:584-590.
21. Lave T, Dupin S, Schmitt M, Kapps M, Meyer J, Morgenroth B, Chou RC, Jaeck D, and Coassolo P (1996) Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica 26:839-851.
22. Mahmood I and Balian JD (1996a) Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J Pharm Sci 85:411-414.
23. Mahmood I and Balian JD (1996b) Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887-895.
24. Mordenti J (1985) Forecasting cephalosporin and monobactam antibiotic half-lives in humans from data collected in laboratory animals. Antimicrob Agents Chemother 27:887-891.
25. Ramji JV, Austin NE, Boyle GW, Chalker MH, Duncan G, Fairless AJ, Hollis FJ, McDonnell DF, Musick TJ, and Shardlow PC (2001) The disposition of gemifloxacin, a new fluoroquinolone antibiotic, in rats and dogs. Drug Metab Dispos 29:435-442.
26. Russel FG, Wouterse AC, and Van Ginneken CA (1989) Physiologically based pharmacokinetic model for the renal clearance of iodopyracet and the interaction with probenecid in the dog. Biopharm Drug Dispos 10:137-152.
27. Sanwald-Ducray P and Dow J (1997) Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling. Xenobiotica 27:189-201.
28. Sasabe H, Tsuji A, and Sugiyama Y (1998) Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. J Pharmacol Exp Ther 284:1033-1039.
29. Schaefer WH (1992) Formation of a carbamoyl glucuronide conjugate of carvedilol in vitro using dog and rat liver microsomes. Drug Metab Dispos 20:130-133.
30. Schaer GL, Fink MP, Chernow B, Ahmed S, and Parrillo JE (1990) Renal hemodynamics and prostaglandin E2 excretion in a nonhuman primate model of septic shock. Crit Care Med 18:52-59.
31. Siefert HM, Domdey-Bette A, Henninger K, Hucke F, Kohlsdorfer C, and Stass HH (1999) Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother 43 (Suppl B):69-76.
32. Stein GE (1996) Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis 23 (Suppl 1):S19-S24.
33. Takahata M, Mitsuyama J, Yamashiro Y, Araki H, Yamada H, Hayakawa H, Todo Y, Minami S, Watanabe Y, and Narita H (1997) T-3811, a novel des-F(6)-quinolone: study of pharmacokinetics in animals, in Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy; Ontario, Canada. pp 173 F160, American Society for Microbiology, Washington, DC.
34. Takahata M, Mitsuyama J, Yamashiro Y, Yonezawa M, Araki H, Todo Y, Minami S, Watanabe Y, and Narita H (1999) In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother 43:1077-1084.
35. Ward KW, Azzarano LM, Bondinell WE, Cousins RD, Huffman WF, Jakas DR, Keenan RM, Ku TW, Lundberg D, Miller WH, et al. (1999) Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist. Drug Metab Dispos 27:1232-1241.